Join Growin Stock Community!

Trinity biotech plcTRIB.US Overview

US StockHealthcare
(No presentation for TRIB)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

TRIB AI Insights

TRIB Overall Performance

TRIB AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

TRIB Recent Performance

-1.93%

Trinity biotech plc

0.05%

Avg of Sector

-0.31%

S&P500

TRIB PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

TRIB Key Information

TRIB Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

TRIB Profile

Trinity Biotech plc acquires, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes. It also develops, manufactures, and sells products in the immunofluorescence assay, enzyme-linked immunosorbent, western blot, and line immunoassay formats; and provides reagent products, such as ACE, bile acids, lactate, oxalate, and glucose-6-phosphate dehydrogenase for diagnosis of liver and kidney diseases, as well as haemolytic anaemia. In addition, the company sells raw materials to the life sciences industry and research institutes. It serves public health authorities, non-governmental organisations, and clinical and reference laboratories through its direct sales force, as well as through a network of independent distributors and strategic partners. Trinity Biotech plc was incorporated in 1992 and is headquartered in Bray, Ireland.

Price of TRIB

TRIB FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

TRIB Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.52
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.28
PB Ratio
5.11
Price-to-FCF
-
METRIC
VALUE
vs. INDUSTRY
Gross Margin
32.45%
Net Margin
-73.78%
Revenue Growth (YoY)
-15.52%
Profit Growth (YoY)
-20.02%
3-Year Revenue Growth
-15.94%
3-Year Profit Growth
-12.81%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-3.52
PE Ratio (TTM)
-
Forward PE
-
PS Ratio (TTM)
0.28
PB Ratio
5.11
Price-to-FCF
-
Gross Margin
32.45%
Net Margin
-73.78%
Revenue Growth (YoY)
-15.52%
Profit Growth (YoY)
-20.02%
3-Year Revenue Growth
-15.94%
3-Year Profit Growth
-12.81%

  • When is TRIB's latest earnings report released?

    The most recent financial report for Trinity biotech plc (TRIB) covers the period of 2025Q2 and was published on 2025/06/30. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TRIB's short-term business performance and financial health. For the latest updates on TRIB's earnings releases, visit this page regularly.

  • What is the operating profit of TRIB?

    According to the latest financial report, Trinity biotech plc (TRIB) reported an Operating Profit of -3.04M with an Operating Margin of -27.73% this period, representing a growth of 24.95% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is TRIB's revenue growth?

    In the latest financial report, Trinity biotech plc (TRIB) announced revenue of 10.97M, with a Year-Over-Year growth rate of -30.77%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does TRIB have?

    As of the end of the reporting period, Trinity biotech plc (TRIB) had total debt of 112.56M, with a debt ratio of 1.13. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does TRIB have?

    At the end of the period, Trinity biotech plc (TRIB) held Total Cash and Cash Equivalents of 1.55M, accounting for 0.02 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Is TRIB's EPS continuing to grow?

    According to the past four quarterly reports, Trinity biotech plc (TRIB)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.32. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of TRIB?

    Trinity biotech plc (TRIB)'s Free Cash Flow (FCF) for the period is -1.71M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 68.91% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.